AIDS Therapies

Open Label Access to Investigational Anti-HIV Compound 1529U89 Begins

Published in AIDS Weekly, August 18th, 1997

A worldwide open label clinical trial of the investigational anti-HIV drug known as 1592 has begun and is expected to enroll up to 2,400 qualified adult AIDS patients in the United States by the end of 1997.

Based on safety data collected in this open label trial, as well as results of ongoing Phase II and III clinical studies, a larger international expanded access program for 1592 is expected to begin in 1998. 1592 is a nucleoside analogue reverse transcriptase inhibitor.

Investigators for the open label study are now actively enrolling patients through approximately 65 clinical trial sites located throughout the country. Entry into the study in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry